GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Price-to-Free-Cash-Flow

ValiRx (LSE:VAL) Price-to-Free-Cash-Flow : N/A (As of May. 05, 2024)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx Price-to-Free-Cash-Flow?

As of today (2024-05-05), ValiRx's share price is £0.0325. ValiRx's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.03. Hence, ValiRx's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for ValiRx's Price-to-Free-Cash-Flow or its related term are showing as below:

LSE:VAL's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.89
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

ValiRx's Free Cash Flow per Share for the six months ended in Jun. 2023 was £-0.01. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was £-0.03.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 55.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 64.60% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 56.10% per year.

During the past 13 years, ValiRx's highest 3-Year average Free Cash Flow per Share Growth Rate was 73.30% per year. The lowest was 13.40% per year. And the median was 54.90% per year.


ValiRx Price-to-Free-Cash-Flow Historical Data

The historical data trend for ValiRx's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Price-to-Free-Cash-Flow Chart

ValiRx Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ValiRx Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ValiRx's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, ValiRx's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ValiRx's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ValiRx's Price-to-Free-Cash-Flow falls into.



ValiRx Price-to-Free-Cash-Flow Calculation

ValiRx's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.0325/-0.028
=N/A

ValiRx's Share Price of today is £0.0325.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ValiRx's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

ValiRx  (LSE:VAL) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


ValiRx Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of ValiRx's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx (LSE:VAL) Business Description

Industry
Traded in Other Exchanges
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.